UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

UCLA’s Christopher Seet receives $2.9M NCI grant to advance cell-based cancer treatments

Christopher Seet received a $2.9 million R37 MERIT Award from NCI to advance the development of innovative T cell therapies for cancer. He is an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Keytruda improves outcomes in soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.

November 15, 2024

Vol.50 No.43

In Brief

UCLA researchers awarded $2.5M grant from BMS Foundation to increase lung cancer screening in underserved communities

A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County.

November 08, 2024

Vol.50 No.42

In Brief

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s urology department was awarded $6 million from the California Department of Health Care Services to continue providing care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.

October 25, 2024

Vol.50 No.40

In Brief

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Luca Valle, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA, was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs to develop new methods to better understand the clinical scope and biological factors that lead to prostate cancer coming back after radiation therapy.

October 25, 2024

Vol.50 No.40

Clinical Roundup

Study finds common breast cancer treatments may speed aging process

A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center revealed that common breast cancer treatments, including chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors.

October 11, 2024

Vol.50 No.38

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

YOU MAY BE INTERESTED IN

UCLA’s Christopher Seet receives $2.9M NCI grant to advance cell-based cancer treatments

Keytruda improves outcomes in soft tissue sarcoma

UCLA researchers awarded $2.5M grant from BMS Foundation to increase lung cancer screening in underserved communities

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Study finds common breast cancer treatments may speed aging process

Renew today!

Subscriber content

Never miss an issue!

Login